Icro Meattini, Associate Professor of Radiation Oncology at the University of Florence, shared a post on X:
“Breast-Conserving Therapy is safe & effective for BRCA1/2 carriers—no impact on OS or DMFS.
CBC risk (esp. in BRCA1) supports considering bilateral mastectomy.
Personalised decisions, early BRCA testing & expert counselling are key.”
Icro Meattini emphasized that breast-conserving therapy is a safe and effective option for BRCA1 and BRCA2 carriers, with no effect on overall or distant metastasis-free survival.
He also noted the importance of considering bilateral mastectomy, particularly in BRCA1 cases, and highlighted the role of early BRCA testing and personalized counseling.
More posts featuring Icro Meattini.
